REGN — REGENERON PHARMACEUTICALS, INC. — Income statement

From the XBRL facts of the company's SEC filings. USD, millions, except per-share figures. Latest filing read: 2026-10-30.

Annual · Quarterly   |   Latest filing · As first reported   |   Download all statements (Excel)

Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025 TTM Sep 2026
Revenues 8,497.1 16,071.7 12,172.9 13,117.2 14,202.0 14,342.9 16,896.2‡
Total revenues 8,497.1 16,071.7 12,172.9 13,117.2 14,202.0 14,342.9 16,896.2‡
Cost of revenues 491.9 - - - - - -
Gross profit 8,005.2‡ - - - - - -
Selling, general and administrative 1,346.0 1,824.9 2,115.9 2,631.3 2,954.4 2,700.0 2,762.6‡
R&D expenses 2,647.0 2,860.1 3,592.5 4,439.0 5,132.0 5,850.2 6,595.9‡
Other operating expenses, total 435.6‡ 2,439.9‡ 1,725.6‡ 1,999.8‡ 2,124.9‡ 2,214.8‡ 2,673.2‡
Operating income (GAAP, as reported) 3,576.6 8,946.8 4,738.9 4,047.1 3,990.7 3,577.9 4,864.5‡
Operating income excl. unusual items (S&P method) 3,576.6‡ 8,946.8‡ 4,738.9‡ 4,047.1‡ 3,990.7‡ 3,577.9‡ -
Interest expense 56.9 57.3 59.4 73.0 55.2 43.8 46.7‡
Net interest expenses (56.9)‡ (57.3)‡ (59.4)‡ (73.0)‡ (55.2)‡ (43.8)‡ (46.7)‡
Other non-operating income (expenses) 290.7 436.3 179.3 225.2 844.4 1,696.6 869.0‡
Total unusual items 0.0‡ 0.0‡ (195.0)‡ - - - -
EBT excl. unusual items 3,810.4‡ 9,325.8‡ 5,053.8‡ 4,199.3‡ 4,779.9‡ 5,230.7‡ 5,686.8‡
EBT incl. unusual items 3,810.4 9,325.8 4,858.8 4,199.3 4,779.9 5,230.7 5,686.8‡
Income tax expense 297.2 1,250.5 520.4 245.7 367.3 725.8 869.4‡
Earnings from continuing operations 3,513.2‡ 8,075.3‡ 4,338.4‡ 3,953.6‡ 4,412.6‡ 4,504.9‡ 4,817.4‡
Net income 3,513.2 8,075.3 4,338.4 3,953.6 4,412.6 4,504.9 4,817.4‡
NI to common incl. extra items 3,513.2‡ 8,075.3‡ 4,338.4‡ 3,953.6‡ 4,412.6‡ 4,504.9‡ 4,817.4‡
NI to common excl. extra items 3,513.2‡ 8,075.3‡ 4,338.4‡ 3,953.6‡ 4,412.6‡ 4,504.9‡ 4,817.4‡
Revenue per share 78.97‡ 152.05‡ 113.66‡ 122.94‡ 131.62‡ 137.12‡ 164.24‡
Basic EPS 32.65 76.40 40.51 37.05 40.90 43.07 46.83‡
Basic weighted average shares 107.6 105.7 107.1 106.7 107.9 104.6 102.9‡
Diluted EPS 30.52 71.97 38.22 34.77 38.34 41.48 45.17‡
Diluted weighted average shares 115.1 112.2 113.5 113.7 115.1 108.6 106.7‡
Normalized net income (S&P method, 37.5 %) 2,381.5‡ 5,828.6‡ 3,158.6‡ 2,624.6‡ 2,987.4‡ 3,269.2‡ 3,554.3‡
Normalized basic EPS (S&P method) 22.13‡ 55.14‡ 29.49‡ 24.60‡ 27.69‡ 31.25‡ 34.55‡
Normalized diluted EPS (S&P method) 20.69‡ 51.95‡ 27.83‡ 23.08‡ 25.96‡ 30.10‡ 33.33‡
EBITDA 3,812.5‡ 9,233.0‡ 5,080.3‡ 4,468.1‡ 4,473.6‡ 4,121.6‡ 5,377.4‡
EBIT 3,576.6‡ 8,946.8‡ 4,738.9‡ 4,047.1‡ 3,990.7‡ 3,577.9‡ 4,864.5‡
Effective tax rate 7.8%‡ 13.4%‡ 10.7%‡ 5.9%‡ 7.7%‡ 13.9%‡ 15.3%‡

‡ derived by arithmetic from reported figures (a fourth quarter is the year less nine months). † read from a substitute line. § reported in a note, not on the face of the statement. “-” not reported. NM not meaningful. Normalized rows follow the S&P method: pre-tax income excluding unusual items, a flat 37.5 % tax rate, less minority interest.

By product or service

Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025 TTM Sep 2026
Revenue
Collaboration Revenue 1,186.1 3,673.3 4,914.1 5,503.1 6,057.8 7,331.2 -
LIBTAYO Net Product Sales - 306.3 447.5 863.1 1,216.8 1,452.2 -
Other Products - - - 0.0 0.0 10.1 -
Product 5,567.6 12,117.2 6,893.7 7,078.0 7,629.2 6,309.1 -
Product And Service Other 557.0 281.2 365.1 536.1 515.0 702.6 -
Sanofi Collaboration Revenue - - 2,855.7 - - - -

By geography

Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025 TTM Sep 2026
Revenue
US - 12,117.2 6,893.7 - - - -

Segment figures as the company tagged them in its filings, one breakdown per table; members need not sum to the total.